Home / Business and Economy / Grifols Eyes U.S. IPO for Biopharma Arm
Grifols Eyes U.S. IPO for Biopharma Arm
25 Mar
Summary
- Spanish drugmaker Grifols approved a U.S. IPO for its biopharma division.
- The IPO aims to raise capital to strengthen its balance sheet and cut debt.
- This move supports self-sufficiency by creating a U.S.-based plasma business.
Grifols, a Spanish pharmaceutical company specializing in plasma-derived medicines, announced on Tuesday its approval for a U.S. initial public offering (IPO) of its U.S. biopharma business. The company intends to offer a minority stake through this IPO, while the parent entity will retain its listing in Spain and majority control over the U.S. operations.
This strategic transaction is designed to bolster Grifols' vision of self-sufficiency, creating an independent U.S. entity that does not depend on plasma, manufacturing, or supply from outside the United States. The capital raised from the IPO is slated to fortify its balance sheet, reduce existing debt, and fund investments in key markets.
The company previously indicated in February that it anticipated core earnings to surge by over a quarter in 2026, with continued debt reduction efforts following a more than doubling of profits in 2025. Grifols affirmed its commitment to expanding its plasma and diagnostics businesses in other significant global markets.
